

REGISTERED NUMBER: 08629933 (England and Wales)

Unaudited Financial Statements

For The Year Ended 31 July 2018

for

ARISE PHARMA LTD

Contents of the Financial Statements
For The Year Ended 31 July 2018

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	4

ARISE PHARMA LTD

Company Information

For The Year Ended 31 July 2018

DIRECTORS:

Mrs M Jaykumar Jani
V B Soni
J Pradyuman Jani

SECRETARY:

J Pradyuman Jani

REGISTERED OFFICE:

79 College Road
Harrow
Middlesex
Middlesex
HA1 1BD

REGISTERED NUMBER:

08629933 (England and Wales)

ACCOUNTANTS:

Ayman Tyler Associates
Accountants & Tax Advisers
79 College Road
Harrow
Middlesex
HA1 1BD

ARISE PHARMA LTD (REGISTERED NUMBER: 08629933)**Balance Sheet**
31 July 2018

	Notes	31.7.18 £	£	31.7.17 £	£
FIXED ASSETS					
Tangible assets	4		1		74
Investments	5		<u>276,110</u>		<u>246,110</u>
			<u>276,111</u>		<u>246,184</u>
CURRENT ASSETS					
Debtors	6	174,350		131,600	
Cash at bank		<u>785</u>		<u>19,666</u>	
		<u>175,135</u>		<u>151,266</u>	
CREDITORS					
Amounts falling due within one year	7	<u>176,012</u>		<u>128,824</u>	
NET CURRENT (LIABILITIES)/ASSETS			<u>(877)</u>		<u>22,442</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			<u>275,234</u>		<u>268,626</u>
CREDITORS					
Amounts falling due after more than one year	8		<u>154,619</u>		<u>216,000</u>
NET ASSETS			<u><u>120,615</u></u>		<u><u>52,626</u></u>
CAPITAL AND RESERVES					
Called up share capital			1,000		1,000
Retained earnings			<u>119,615</u>		<u>51,626</u>
SHAREHOLDERS' FUNDS			<u><u>120,615</u></u>		<u><u>52,626</u></u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 July 2018.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 July 2018 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.
- (b)

The notes form part of these financial statements

Balance Sheet - continued
31 July 2018

The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors on 18 October 2018 and were signed on its behalf by:

Mrs M Jaykumar Jani - Director

J Pradyuman Jani - Director

Notes to the Financial Statements
For The Year Ended 31 July 2018

1. STATUTORY INFORMATION

ARISE PHARMA LTD is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery etc - 33% on cost

Investments in associates

Investments in associate undertakings are recognised at cost.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2017 - NIL).

Notes to the Financial Statements - continued
For The Year Ended 31 July 2018

4. TANGIBLE FIXED ASSETS

	Plant and machinery etc £
COST	
At 1 August 2017 and 31 July 2018	<u>857</u>
DEPRECIATION	
At 1 August 2017	783
Charge for year	<u>73</u>
At 31 July 2018	<u>856</u>
NET BOOK VALUE	
At 31 July 2018	<u>1</u>
At 31 July 2017	<u>74</u>

5. FIXED ASSET INVESTMENTS

	31.7.18 £	31.7.17 £
Participating interests	110	110
Loans to undertakings in which the company has a participating interest	246,000	246,000
Other loans	<u>30,000</u>	<u>-</u>
	<u>276,110</u>	<u>246,110</u>

Additional information is as follows:

		Interest in associate £
COST		
At 1 August 2017 and 31 July 2018		<u>110</u>
NET BOOK VALUE		
At 31 July 2018		<u>110</u>
At 31 July 2017		<u>110</u>
	Loans to associates £	Totals £
At 1 August 2017	246,000	246,000
New in year	<u>-</u>	<u>30,000</u>
At 31 July 2018	<u>246,000</u>	<u>276,000</u>
	Other loans £	
	-	
	<u>30,000</u>	
	<u>30,000</u>	

Notes to the Financial Statements - continued
For The Year Ended 31 July 2018

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31.7.18	31.7.17
	£	£
Trade debtors	166,000	130,000
Other debtors	8,350	1,600
	<u>174,350</u>	<u>131,600</u>

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31.7.18	31.7.17
	£	£
Trade creditors	1	-
Taxation and social security	36,156	25,916
Other creditors	139,855	102,908
	<u>176,012</u>	<u>128,824</u>

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

	31.7.18	31.7.17
	£	£
Other creditors	<u>154,619</u>	<u>216,000</u>

Unsecured Directors Loan

Unsecured Director's Loan of £154,619 given by Mr Jaykumar Pradyuman Jani was interest free and subordinated in favour of third party creditors. The loan is repayable after 5 years.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.